The Wegovy Dose Question Everyone Asks (Finally Answered)

Wegovy at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2021
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Cash price (US): $1,300-$1,400/month without insurance
• Receptor target: GLP-1 receptor

Here's the core rule for Wegovy dosing: titrate slowly, hold each step long enough, and don't try to outpace your body. Wegovy escalates from 0.

Standard Dosing Schedule for Wegovy

Wegovy escalates from 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, with each step held for at least four weeks. The 2.4 mg maintenance dose drives the headline weight-loss results.

The typical schedule for Wegovy is once weekly via subcutaneous injection (single-dose pen). Half-life of approximately 7 days explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for Wegovy holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Wegovy is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 7 days) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Wegovy side effects and the cost angle of dose escalation in Wegovy cost.

What the Trials Used

Published trial data for Wegovy comes primarily from: STEP 1 (Wilding 2021, NEJM) — 14.9% mean weight loss at 68 weeks. SELECT (Lincoff 2023, NEJM) — 20% reduction in major cardiovascular events in non-diabetic patients with obesity.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Wegovy: the personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy apply.

Bottom Line

Wegovy dosing isn't intuitive but it isn't complicated either. Follow the schedule, talk to your prescriber when something feels off, and don't make changes on your own.

Frequently Asked Questions

Related Reading

• What Is Wegovy? Everything You Should Know Before Starting
• Wegovy Side Effects: 7 Things to Watch For (and How to Manage Them)
• Wegovy Results: Realistic Expectations vs. Trial Headlines
• Why Wegovy Costs So Much (and 5 Ways to Pay Less)
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.